GlassScriptPhysician profile
Abhishek Gulati
NPI 1629380308
$16,950.04
in general payments reported to CMS, 2019-2025
37 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,209 · 2020: $443 · 2021: $470 · 2022: $554 · 2023: $1,481 · 2024: $10K · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,850 · Food and Beverage: $4,390 · Consulting Fee: $4,000 · Education: $34.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,850.31 |
| Food and Beverage | $4,389.54 |
| Consulting Fee | $4,000.00 |
| Education | $34.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $4,972.64 | 2024 | |
| US Endoscopy | $4,000.00 | 2024 | |
| Boston Scientific Corporation | $2,264.18 | 2019-2025 | Exalt Model D, Axios, Resolution 360 Clip |
| Abbvie INC. | $1,627.55 | 2019-2025 | |
| Apollo Endosurgery US INC | $1,011.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $599.66 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $254.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $249.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.67 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $200.15 | 2019-2024 | Stelara, Tremfya |
| Olympus America INC. | $177.86 | 2024 | Single Use Aspiration Needle Na-U200h, Endoclot Phs |
| Ethicon US, LLC | $171.35 | 2024 | Harmonic, Enseal, Echelon Endopath |
| Qol Medical, LLC | $144.82 | 2022-2025 | Sucraid, Sucraid |
| Celgene Corporation | $111.21 | 2023-2024 | Zeposia |
| Ambu INC. | $108.05 | 2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $82.44 | 2023 | Esophyx |
| Pfizer INC. | $76.09 | 2019-2022 | |
| Lilly USA, LLC | $72.59 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $72.07 | 2019-2023 | Ocaliva |
| Ardelyx, INC. | $68.12 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $61.59 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $60.57 | 2019 | |
| Nestle Healthcare Nutrition INC. | $56.43 | 2022-2023 | |
| Celltrion USA INC. | $47.67 | 2023-2025 | Zymfentra, Vegzelma |
| Cook Medical LLC | $31.73 | 2019 | |
| Allergan, INC. | $28.97 | 2020 | |
| Medtronic, INC. | $27.01 | 2024 | Synchromedii |
| Vivus LLC | $24.17 | 2022 | |
| Novo Nordisk INC | $22.71 | 2025 | Wegovy |
| Shire North American Group INC | $20.78 | 2019 | |
| Shionogi INC | $20.23 | 2019 | |
| Alfasigma USA, INC. | $15.60 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.88 | 2020 | |
| Genzyme Corporation | $12.86 | 2023 | |
| Endo Pharmaceuticals INC. | $12.41 | 2019 | |
| Braintree Laboratories, INC. | $11.39 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $11.19 | 2023 | Lockado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.